Friday, November 29, 2013

Arrayit Corp. (ARYC) Sells NanoPrint™ Instrument to Top Canadian Research Center

Life sciences and molecular diagnostics leader Arrayit reports that it has sold a $166,000 NanoPrint™ LM60PRO Enterprise Level Protein Edition Microarray Printer and accessories to a top research center in Ontario, Canada, for use in the manufacture of protein microarrays for interdisciplinary research applications.

Arrayit protein microarrays contain miniaturized collections of intact proteins, the molecules that comprise the building blocks of all living organisms including humans, plants and animals. These protein microarrays provide researchers with the tools necessary to study the structure and function of proteins, which are integral to understanding diverse fundamental research topics such as pharmaceutical compounds, human disease progression, synthetic and stem cell biology, ecology and population genetics.

Arrayit has been selling its patented microarray technology since 1997, and has installed its foundational technology in more than 4,000 laboratories to manufacture an estimated 100 million microarray devices.

The company recently completed a $1 million equity capital raise as well as opened new and expanded Sunnyvale headquarters, which will feature CLIA and ISO laboratories certified with the assistance of DOCRO, an Oxford, Connecticut-based clinical research organization. DOCRO is also assisting the company with its 510(k) submissions to the FDA for OvaDx® and PDx™, the company’s pre-symptomatic diagnostic tests for ovarian cancer and Parkinson’s disease.

For more information, visit www.arrayit.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

ForceField Energy Inc. (FNRG) Two Location LED Installation With Major Latin America Restaurant Developer QSR Could Lead To Many More

ForceField Energy, whose technologies cover significant ground in the renewable and improved energy efficiency landscape, ranging from their exclusive distribution role for premier LED manufacturer, Lightsky, to their patent-pending organic rankine cycle tech (heat recovery and energy conversion process being developed by 51%-owned subsidiary TransPacific Energy), reported another major LED installation deal recently. This announcement comes just six days after their report of an initial $175k purchase order for LED lighting products from burgeoning printing and packaging company, Motivating Graphics Inc., out of Fort Worth, Texas.

The recent announcement details how FNRG has entered into a strategically promising agreement with Master Franchise restaurant developer, QSR International, who has an extensive multi-brand footprint throughout fifteen countries in Latin America and the Caribbean, consisting of some 145 locations. QSR has a keen eye for the energy savings upgrade and improved customer experience available through FNRG’s LED lighting products and initial activity under the agreement will see the company installing their advanced lighting solutions at one KFC and at one Quiznos, out of QSR’s huge portfolio of restaurants.

QSR has other top brands in their lineup like Smashburger, as well as the Asian food franchise, Teriyaki Experience, granting them considerable potential for regional market development right across the sector’s primary consumer areas. Given QSR’s rapidly developing load out of owned, operated and under-development restaurants, this agreement is a huge foot in the door for FNRG, which now stands poised to secure an LED roll-out across the remaining QSR infrastructure. There isn’t much standing in QSR’s way to making that call either, as FNRG’s turnkey LED lighting solutions offer existing locations and soon-to-be-opened locations a simple retrofit/installation process that significantly improves both operating cost efficiencies and overall environmental aesthetics.

The KFC/Quiznos implementations will be a rigorous trialing of the LED retrofit and FNRG is gunning to impress QSR on both the aesthetic and performance fronts, hungry to capture the additional territory that QSR’s large and growing footprint of restaurants represents in the lucrative Latin America and Caribbean markets. QSR currently owns the Master Franchise for Quiznos in this market and they have around 57 more locations slated to open in the next several years via development agreement commitments.

CEO of FNRG, David Natan, explained that the long hours of continuous operation and mounting costs of power typical in this industry make LED installations an ideal choice, a choice which creates an exceptionally fast return on investment. Natan emphasized the strength of QSR’s presence within this highly competitive market, as well as their superb positioning for further growth, tipping his hat to investors that the 50% to 80% savings possible through installation of FNRG’s high-quality, competitively priced LED solutions would lead to a much wider adoption by QSR.

President of QSR, Richard Eisenberg, called the overall value of QSR’s lighting solutions “clear and simple,” further touting the quality, speed and service FNRG is known for as being perfectly aligned with QSR’s own high-growth, quick-service restaurant mentality. Encouraging words from Eisenberg that spell big future sales for FNRG, which has exclusive distribution rights for Lightsky in the U.S., as well as in Canada, Mexico, Latin America, the Caribbean, and part of Europe.

For more info on ForceField Energy, visit www.ForceFieldEnergy.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Chanticleer Holdings, Inc. (HOTR) Channeling Profit Potential of Classic Good Eats at Global Scale

Chanticleer Holdings seeks to become a global success in the highly competitive restaurant sector. The Charlotte, North Carolina-based company’s primary focus is currently on expanding one of the most iconic and well-known U.S. restaurant brands to date to emerging international markets. As of now, it wholly or partially owns Hooters restaurants in South Africa, Hungary, and strategic parts of Brazil. It also has a joint venture with the current Hooters franchisee in Australia, and with a group of private equity investors holds ownership in Hooters of America (HOA), a privately held company. Currently, HOA is an operator and the franchisor of over 412 Hooters® restaurants in 28 countries.

Mapping out its current territorial holdings, Chanticleer Holdings estimates there’s room for over 75 Hooters locations across the globe. The company selects territories for targeting based on select criteria with the following elements:

International Hooters territory with no existing franchisee or a territory to partner with current franchisee
Strong local market dynamics, including compelling demographics and economic growth measures
Capacity to partner with highly-experienced and well-capitalized restaurant operators in local international market
Identification of restaurant locations with attractive leasehold economies
Maintenance of focused growth strategy with focus on expected ROI and increasing shareholder value

As noted in a recent article on Seeking Alpha, Chanticleer Holdings hopes to have four more Hooters locations in Brazil by the end of 2013, bringing its goal total to 10 locations up-and-running globally by year-end. The first location is set to be in Rio de Janeiro, Brazil. The timing for having this classic brand in place at this location will be perfect, just in time for the 2014 FIFA World Cup and 2016 Summer Olympics. Other market factors such as low unemployment and Brazilian income growth of 10% also show these international locations’ profit potential.

Aside from channeling the popular Hooters brand on a global scale, Chanticleer Holdings has been capitalizing on attractive domestic opportunities. The company assumed operating control of a five-location burger joint located in Charlotte, American Roadside Burgers. It acquired the 100% acquisition of this restaurant chain back in September of this year.

Chanticleer Holdings continues to grow on a worldwide scale and seek new opportunities for diversification. With an experienced management team in place, it just may well have the markings of being a global success.

For more information, visit www.chanticleerholdings.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Calpian, Inc. (CLPI) E-Commerce Services Offer the Best of Both Worlds

E-commerce company Calpian offers the best of both worlds in electronic commerce. The company achieves steady cash flow through its U.S. payments business, Calpian Commerce, and explosive growth with Money-on-Mobile, its India-based mobile payments product.

Calpian Commerce, a wholly owned subsidiary of Calpian, Inc., offers the merchant community a full, integrated suite of payment processing services and related software-enabling products, including credit and debit card processing, ACH, mobile acceptance and gateway payment solutions. These services and products are provided to U.S. merchants operating in both brick-and-mortar facilities and through the Internet, as well as in settings that require wired and wireless/portable payment solutions. Calpian Commerce’s products and services are delivered to merchants through a direct sales force, ISOs, and Agent Banks.

Money-on-Mobile, Calpian’s Indian subsidiary, originated in 2012 and is a prepaid mobile payment solution. Money-on-Mobile gives customers the ability to use their mobile phones to buy goods and services or to transfer funds from one cell phone to another through simple SMS text functionality. To date, Money-on-Mobile has been accessed by more than 75 million unique telephone customers at over 167,000 retail locations in India.

For more information about Calpian and its services, visit www.calpian.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

LDMicro Conference Update: Upcoming Event Sees Record-Breaking Response, Hotel Sell-Outs

Ahead of its sixth annual LDMicro investor conference next week, LDMicro founder and President Chris Lahiji reports the close of conference registration and says that this year’s conference has achieved record-breaking results on several fronts.

“The response has been overwhelmingly positive,” said Lahiji. “We’re pleased to say that we’ve broken every LDMicro conference numerical record in the last 30 days. We are looking forward to wrapping up the year with a successful and exciting 2013 conference.”

The LDMicro Conference will run December 3-5 at the Luxe Hotel on Sunset Blvd. in Los Angeles, Calif., featuring hundreds of small-cap and micro-cap companies that will present to more than 1,000 attending investors.

Individuals or companies that were registered but are unable to attend should inform LDMicro of their expected absence. While Los Angeles has plentiful hotel accommodations, two of the close proximity hotels are now fully booked.

“The Luxe Sunset and the Hotel Angeleno are both sold out. The beautiful Hotel Bel Air still has rooms (mention LD Micro) and is only two miles away,” says Lahiji. “The best part is we have a fantastic sponsor that will be providing shuttle service to and from the event.”

For more information, visit http://www.ldmicro.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Methes Energies International Ltd. (MEIL) Advances toward Broader Goals with Wake of Consistent, Progressive Success

Methes Energies’ suite of biodiesel solutions has earned the company the reputation of a highly respected player in the North American biodiesel sector. The company’s cutting-edge solutions are designed for large and small scale biodiesel producers as well as for entrepreneurs who want the independence of producing their own fuel.

The company’s overarching goal is to become a top maker and service provider of compact continuous flow biodiesel processors, processor systems, training, maintenance, and related biodiesel services. In its nine-year history the company has made considerable advances in achieving this goal.

In 2007, Methes developed the Denami 600, the industry’s first compact, fully automated state-of-the-art continuous flow biodiesel processor that runs on a wide variety of feedstocks. The Denami 600 produces quality, top-grade B100 biodiesel fuel that meets or exceeds current ASTM standards in 5 million liters (1.3 million gallons) per year increments.

In 2011 the company continued its innovation and successfully commissioned a continuous flow, non-chemical pre-treatment processor that converts the free fatty acids (FFA) found in most biodiesel feedstock to less than 1 percent.

Aside from other biodiesel solutions, Methes also covers all aspects of the engineering, manufacturing, logistic, marketing and distribution processes. Heading its development and growth initiatives is a team of founders with more than 20 years of combined experience in the biodiesel field.

For more information, visit www.methes.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Wednesday, November 27, 2013

Echo Therapeutics, Inc. (ECTE) Nears CE Mark Approval for Revolutionary Non-Invasive Continuous Glucose Monitoring System Symphony® CGM

Echo Therapeutics, whose Symphony® CGM System (incorporating the company’s proprietary skin permeation/prep technology, Prelude®), offers a needle-free/non-invasive solution for reliable, continuous blood glucose data monitoring, made some major waves yesterday with the announcement that multi-center clinical trials of the device in critical care unit surgical patients produced positive results.

With some 630 plus readings across a 32 subject study, Symphony CGM yielded superb results, bringing in a 97.9% clinical accuracy rating with the remaining 1.8% being merely benign errors (via Continuous Glucose-Error Grid Analysis). This places the device well within the primary safety and efficacy targets set for the study and thus ECTE is now definitively on track for marketing approval in Europe via a CE Mark Technical File submission anticipated for Q4 this year.

With what is the largest study to date (where all components were finally utilized in a clinical environment) successfully tucked under their belts and with solid safety data showing no adverse side effects, ECTE is confident they have their hands on a real answer now for hospital critical care units to be able to implement truly robust glycemic control protocols, a situation that will invariably improve clinical outcomes for patients, as well as operating bottom lines. Of course, the functionality of the device is the same for individual diabetics and this incredible marriage of technologies, which includes a transdermal sensor and wireless transceiver, represents a paradigm shift away from extant FDA-approved continuous blood glucose monitoring systems, which are needle-based and require insertion of a monitoring sensor under the patient’s skin. This inserted sensor methodology produces risk of infection and the inflammation or bleeding associated with it is deleterious to patient quality of life, a state of affairs totally averted by use of the non-invasive Symphony CGM System.

This system becoming ubiquitous translates directly into improved quality of life and care for diabetics as continuous access to glucose values and changes helps identify an individual’s tendency to drift into hyperglycemic or hypoglycemic zones. This is a godsend for the estimated 347M humans worldwide in 2013 suffering from the chronic disease and, with projections on that figure set to rise 55% by 2035 to just over 592M, ECTE shareholders are poised to see some serious upside.

Moreover, the Prelude SkinPrep System technology, which is incorporated into Symphony, looks to have massive impact potential in the transdermal drug delivery space, potentially including drugs that have high and low molecular weights, another key aspect of the overall platform’s striking distance within target markets. The Prelude skin permeation process enhances efficacy (possibly as much as 100 times that of untreated skin in transdermal topical drug delivery) and potentially enables safe, rapid uptake of even topical anesthetic creams. Symphony CGM derives significant benefits from this skin prep technology in the diabetic patient class and the improved continuous sensing thusly enabled directly offsets one of the primary cost vectors here nicely, as glucose monitoring accounts for a significant portion of overall care expenses for diabetic patients.

With some 25.8M diabetics and climbing in 2011 alone here in the U.S. (upwards of 8.3% of the population with 1.9M new cases each year reported in ages 20 and up) and another 60M (around 10%) just in the EU, ECTE is tapping into a gigantic market where the consumer is hungry for change. Especially in the aging/elderly, the largest patient group in the category, the non-invasive Symphony system will draw mass appeal and for the clinical environment the device’s efficacy, enabling of obvious procedural improvements, and ultimately quality of care, could spark a firestorm of industry adoption.

Regulatory studies successfully completed for the Q4, CE Mark Technical File submission, ECTE was confident in their conference call yesterday (877-870-5176 using Replay Pin 10037555) that this wireless little marvel of a product was going places and investors will want to keep a close eye on the Symphony as commercialization advances.

More info on Echo Therapeutics is available at www.EchoTx.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Galena Biopharma (GALE) a Favored Buy, Says Seeking Alpha Contributor

Galena Biopharma was recently the topic of a Seeking Alpha article by contributor “Stock Whisper.” The article discusses the trading activity of Galena stock, recently analyst coverage, as well as current and potential sales figures.

To read the article in its entirety visit http://seekingalpha.com/article/1865671

Shares of Galena have soared nearly 60 percent since November 11 when the company issued its phase I trial results of its Folate Binding Protein (FBP) vaccine for endometrial and ovarian cancer. The rally accrued additional investor interest and was further fueled by analyst action.

Oppenheimer Monday initiated an Outperform rating on Galena’s stock and set a 12-18-month price target of $6.

“The coverage by Oppenheimer came as positive news, as it further strengthens the positive sentiment surrounding the company, which was translated into the share prices yesterday. The pipeline candidates of Galena are indeed promising, having expected blockbuster potential,” the article states.

Referencing Galena’s marketing of Abstral®, for which the company reported $1.2 million in sales before the official product launch, Stock Whisper writes, “Hence, it is right to say that Abstral in the coming quarters may prove to be a major value creator for the company and help pave the way towards a profitable company.”

The article also discusses NeuVax, the company’s potential blockbuster drug for breast cancer treatment and its opportunity in the healthcare market.

“…If we take the same cost for NeuVax, the potential annual sales amount to a stellar $8.4 billion. Even if Galena succeeds in capturing only 10% of the market, the annual sales for the drug would be 840 million. Thus this provides a massive potential for the company, when and if it’s approved.”

In conclusion, the article dubs Galena “a fair investment, with major long term potential. The current price is a profitable entry point for long term investors as the share prices are bound to take off and will bring in huge gains.”

For more information, visit www.galenabiopharma.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

OxySure Systems, Inc. (OXYS) Guided by Innovators with Decades of Experience

OxySure Systems, a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions, has developed a safe and easy-to-use solution to produce medically pure (USP) oxygen from inert powders.
The company owns numerous issued patents and patents pending on this technology, which is designed to make the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems.

OxySure’s efforts are guided by CEO Julian T. Ross, who is also the OxySure founder and technology developer (holds nine patents).

With more than 25 years of experience in technology, manufacturing and finance, Ross has managed development of production capabilities, partnerships and alliances; managed the development of sales, distribution and licensing partnerships; raised in excess of $14 million in debt and equity to fund operations; and took OxySure public in 2011 through an S-1 registration with the Securities and Exchange Commission.

Ross is backed by a highly experienced team of directors and an equally as knowledgeable advisory board. Collectively, the team has experience in healthcare, management, business development, mergers & acquisitions, operations, private practice medicine and more.

For more information, visit www.oxysure.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Monday, November 25, 2013

StreamTrack, Inc. (STTK) Leverages Unique Platform to Provide Full-Circle Services

StreamTrack is a digital media and technology services company that provides an array of audio and video streaming and advertising services through its RadioLoyalty™ platform. The platform is a web-based and mobile player designed for broadcasters and advertisers as a way to manage streaming audio and video content, social media engagement, and ad serving.

On one hand, the platform enables users to listen choose from a database of thousands of radio stations to earn loyalty points that can be redeemed for merchandise.

At the other end of the spectrum, advertisers can utilize the RadioLoyalty platform as a cost-effective means to reach their target audience from one source at scale. Advertisers can pick their desired demographics, formats and geographic areas to launch a targeted campaign.

In the middle are the broadcasters, which use the platform to increase their audience and revenue. The service is free-of-charge for broadcasters, requiring only the time and space in the player. As listeners redeem their RadioLoyalty points for merchandise, the broadcasters are generating revenues. RadioLoyalty is designed to increase listener times to create more bottom-line for these broadcasters.

StreamTrack’s portfolio also includes the following trademarked technologies: UniversalPlayer, WatchThis, AdMaximizer, ReplaceAds, HDIRadio, Jetcast, and StreamTrack Media. Each technology employs a specific strategy to provide broadcasters and content owners with advanced solutions in the entertainment marketplace.

For more information, visit www.StreamTrack.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

Boston Therapeutics, Inc. (BTHE) on Accelerated Path for Drug Development

Boston Therapeutics is a pharmaceutical company focused on the development and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs. The company’s current product pipeline is focused on developing and commercializing the therapeutic molecules PAZ320 for patients with diabetes; and Ipoxyn™ for a wide rand of indications such as anemia and blood loss (injury), cardiovascular disease, and surgical blood supplementation.

The company’s lead product, PAZ320, is a non-systemic, non-toxic, chewable drug candidate that inhibits the enzymes that release glucose from complex carbohydrate in foods during digestion. Boston Therapeutics has developed the PAZ320 drug compound for people with pre-diabetes and diabetes in their daily management of blood glucose levels.

Ipoxyn™ is an injectable prescription drug developed to prevent necrosis and treatment of ischemic conditions which may lead to necrosis, a form of cell injury resulting in the death of cells in living tissue, such as with gangrene. The gloco-protein-based therapeutic agent is applicable to both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support.

OxyFex™ is the company’s veterinary facsimile to Ipoxyn™, designed for the veterinary market as blood replacement and oxygen delivery to damaged or ischemic tissue due to trauma, surgery anemia, and other disease conditions.

Boston Therapeutics’ strategy is to develop PAZ320 and Ipoxyn™ by using the U.S. Food and Drug Administration’s Prescription Drug User Fee Act (PDUFA), which provides an expedited means of drug development.

Moving forward, the company continues to build on its momentum from positive results for PAZ320’s phase 2a safety and efficacy trial, and recently raised $5.3 million to fund ongoing clinical trials for PAZ320. Boston Therapeutics in early November began enrolling patients in a phase IIb clinical study on PAZ320.

For more information, visit: www.bostonti.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

Midwest Energy Emissions Corp. (MEEC) Capitalizing on the EPA’s $10 Billion Mandated Market

Mercury is a serious environmental and human health threat. Mercury exposure destroys the human nervous system and permanently damages the brain, heart, kidneys, lungs, and immune system. Over 50% of mercury emissions in the United States come from coal and oil-fired power plants and the US Environmental Protection Agency (EPA) has issued new regulatory mandates.

The Mercury and Air Toxics Standards (MATS) establish new power plant emission requirements for mercury and other toxic pollutants. These mandates require that all US coal and oil-fired power plants larger than 25 mega-watts must remove roughly 90% of mercury from their emissions by April 16, 2015. The EPA estimates the cost of such emissions compliance to run $9.6 Billion annually.

Traditional approaches to cleaning mercury emissions from power plants include utilizing a Scrubber and Selective Catalytic Reduction (SCR) combination. However, scrubbers cost hundreds of millions of dollars and result in large, complex systems that often cause power plant disruptions. Recent problems with mercury pools of sludge being re-emitted question the effectiveness of this high priced option. Utilities have turned to Powdered Activated Carbon (PAC) or Brominated Activated Carbon (BAC) solutions to meet the 90% mercury reduction requirements. However, Activated Carbon is only effective at removing 70% or less of mercury emissions and at higher injection rates create operational issues and makes fly ash unsalable. A byproduct of coal combustion, utilities sell fly ash ($450 million annually) for use in concrete production and stand to lose an important revenue source.

There is a new patented technology that has been shown to achieve mercury removal levels compliant with MATS at a significantly lower cost and with less operational impact than the currently used methods.

Midwest Energy Emissions owns the rights to the multi-patented Sorbent Enhancement Additive (SEA) technology. The process involves injection of sorbent enhancement additive in minimal amounts into the boiler, which works in support with its proprietary sorbents to insure maximum mercury capture. SEA technology can be specifically customized for each application to match a customer’s fuel type and boiler configuration to optimize results. This allows customers to meet the new, highly restrictive standards the U.S. EPA has set for mercury emissions, in an effective and economical manner with the least disruption to their current equipment and on-going operations.

Midwest Energy Emissions has been conducting highly successful demonstrations of their technology at power plants nationwide and has consistently delivered MATS compliance, cost effectiveness, and fly-ash salability. With these technological and financial advantages Midwest Energy Emissions is perfectly positioned to capture an outsized share of this new $10 Billion market.

For more information, please refer to the company’s website at www.midwestemissions.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

Boston Therapeutics, Inc. (BTHE) on Accelerated Path for Drug Development

Boston Therapeutics is a pharmaceutical company focused on the development and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs. The company’s current product pipeline is focused on developing and commercializing the therapeutic molecules PAZ320 for patients with diabetes; and Ipoxyn™ for a wide rand of indications such as anemia and blood loss (injury), cardiovascular disease, and surgical blood supplementation.

The company’s lead product, PAZ320, is a non-systemic, non-toxic, chewable drug candidate that inhibits the enzymes that release glucose from complex carbohydrate in foods during digestion. Boston Therapeutics has developed the PAZ320 drug compound for people with pre-diabetes and diabetes in their daily management of blood glucose levels.

Ipoxyn™ is an injectable prescription drug developed to prevent necrosis and treatment of ischemic conditions which may lead to necrosis, a form of cell injury resulting in the death of cells in living tissue, such as with gangrene. The gloco-protein-based therapeutic agent is applicable to both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support.

OxyFex™ is the company’s veterinary facsimile to Ipoxyn™, designed for the veterinary market as blood replacement and oxygen delivery to damaged or ischemic tissue due to trauma, surgery anemia, and other disease conditions.

Boston Therapeutics’ strategy is to develop PAZ320 and Ipoxyn™ by using the U.S. Food and Drug Administration’s Prescription Drug User Fee Act (PDUFA), which provides an expedited means of drug development.

Moving forward, the company continues to build on its momentum from positive results for PAZ320’s phase 2a safety and efficacy trial, and recently raised $5.3 million to fund ongoing clinical trials for PAZ320. Boston Therapeutics in early November began enrolling patients in a phase IIb clinical study on PAZ320.

For more information, visit: www.bostonti.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

DreamTeamGroup (DTG) to Provide Real-time Social Media Updates of Sixth Annual LD MICRO Conference

DreamTeamGroup (DTG), a consortium of unique marketing brands that utilizes one dynamic approach to connect publicly traded companies with a variety of investors, will provide the investment community with comprehensive and ongoing social media coverage of the LD MICRO Conference at the Luxe Sunset Bel Air Hotel in Los Angeles, December 3-5, 2013.

To learn more about the presenting companies, visit http://ldmicro.missionir.com/2013.

DTG will utilize its extensive line of business brands to keep the investment community informed on each of the more than 200 companies scheduled to present during the three-day conference.

Chris Lahiji, founder of LD MICRO, emphasized the value of DTG’s coverage, saying, “Six years ago, our goal was to create an event that provided access to those that were passionate about investing in micro-cap companies. Our big issue has always been with space, and the simple fact that we can only host so many people. DreamTeamGroup solves that issue by providing a conduit to the investment community at large so that they too can have direct access to our annual conference through multiple DTG platforms. We are excited for what the future holds and look forward to the day that everyone can get access to their favorite companies.”

DTG will utilize its unique portfolio of business brands and broad social media network to issue blogs, status updates on attending companies as they begin their presentations at the conference, as well as issue special newsletter profiling the event to DTG subscribers.

“We’re honored to be a part of this year’s LD MICRO Conference,” stated Michael McCarthy, managing director of DTG. “DreamTeamGroup is constantly updating its capabilities to apply the latest, most effective social media services necessary to provide comprehensive and real-time coverage of the investor conference.”

To subscribe to ongoing social media updates, follow MissionIR on Facebook (http://facebook.com/MissionIR) or Twitter (http://twitter.com/MissionIR).

For more information, visit www.DreamTeamGroup.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Kingold Jewelry, Inc. (KGJI) Video Chart for Monday, November 25, 2013

KGJI found some legs again on Thursday and Friday to climb off a support level at $1.58 and move back over the 50-day moving average. The chart has made a big move in the last couple months and may be ready to try and take another run at new highs.

To view the video chart, visit the following link: http://www.missionir.com/videos.html

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

AudioCodes Ltd. (AUDC) Partners with Dell Services on Microsoft Lync Implementations

AudioCodes, a prominent supplier of converged voice solutions that enable enterprises and service providers to transition to all-IP voice networks, announced today that Dell Services has selected AudioCodes for enabling Unified Communications with Microsoft® Lync™. The partnerships provide solutions that include industry-leading, Microsoft-certified voice networking products and services, specifically Microsoft Lync, which has experienced an expanding adoption rate by large enterprises.

Dell is entering the worldwide community of AudioCodes One Voice for Microsoft Lync partners, a unified product and service program created to simplify and accelerate voice-enablement for Lync implementations with a complete portfolio of IP Phones, Media Gateways, Enterprise Session Border Controllers (E-SBCs), Survivable Branch Appliances (SBAs), Session Experience Manager (SEM) and complete network management tools, support and professional services for voice. The program facilitates efficient migration to Microsoft Lync and co-existence with telephony systems currently installed in both multi-site and multi-national deployments.

“Dell Services shares AudioCodes’ One Voice for Lync vision, and believes that enterprises can smoothly migrate to Lync, and enjoy the many benefits it brings. AudioCodes’ portfolio enables us to effectively address the needs of our customers in the Lync space,” stated Michael Przytula, Managing Director – Global Communication & Collaboration Practice at Dell Services.

AudioCodes has been selected by Dell as the voice networking solution provider for the company’s Accelerate Program for Microsoft® Lync ™. Enterprises can leverage the Accelerate Program to gain access to bundled consulting services, networking products and user devices to assist with rapidly deployment of a production implementation of Dell’s Lync 2013 based UC solution.

“AudioCodes is excited to be a key voice networking provider of the Dell Accelerate Program for Microsoft Lync 2013. The program provides AudioCodes with broader access to enterprise Lync opportunities worldwide,” said Nimrod Borovsky, Vice President of Marketing at AudioCodes.

For further information, please visit www.audiocodes.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Crossroads Systems, Inc. (CRDS) Introduces Richard K. Coleman, Jr. as New President and CEO

Crossroads Systems, a global provider of data storage solutions, has announced the appointment of Richard K. Coleman, Jr. as its president and chief executive officer. Mr. Coleman had been serving as interim president and chief executive of the Austin, Texas-based company since May, 2013.

Founded in 1996, Crossroads has been awarded more than 100 patents and has been honored with numerous industry awards for data archiving, storage and protection. Its latest product, StrongBox, is a plug and play device that solves data storage and protection challenges while keeping files fully accessible and simplifying long-term preservation.

Coleman says he is happy about the advancements Crossroads has made in the industry and is looking forward to the company’s future, as it continues to expand into markets worldwide.

“Crossroads has made dramatic progress on all fronts in the last six months,” he said. “I’m excited to be part of this team and to help write the next chapter in what will ultimately be the story of a great company.”

The new president and CEO has had a lengthy background as a private investor and business advisor since 1998, having founded Rocky Mountain Venture Services (RMVS) and helping technology companies plan and launch new business ventures and restructuring initiatives. He has also served in a variety of senior operational roles, including CEO of Vroom Technologies, COO of MetroNet Communications, and President of US West Long Distance. In addition, he led Sprint Communications’ Technology Management Division.

Coleman holds a bachelor’s degree from the United States Air Force Academy, an MBA from Golden Gate University, and is a graduate of the United States Air Force Communications Systems Officer School. Currently a guest lecturer for Denver University, focusing on leadership and ethics, he previously served as an adjunct professor for Regis University’s graduate management program.

Under Coleman’s leadership, Crossroads Systems is poised to use its innovative new technologies to deliver its customer-driven solutions that enable proactive data security, advanced data archiving, optimized performance and significant cost-savings.

For more information, visit www.crossroads.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Friday, November 22, 2013

Saleen Automotive, Inc. (SLNN) Announces Production of 30 New SA-30s to Celebrate 30 Years of Automotive Innovation

Saleen Automotive, an American specialty manufacturer of high performance vehicles, technical performance parts, lifestyle accessories and apparel, announced that it will be producing three variations of its SA-30 model to commemorate the 30th anniversary of Steve Saleen as a specialty vehicle manufacturer.

The Saleen Anniversary series vehicles, the sixth edition in the SA series, have become a valuable collectable for enthusiasts due to their exclusivity and incredibly low production volumes. In addition to this intrinsic value, each anniversary edition vehicle also traditionally features a balanced combination of Saleen legacy and innovative, future enhancements.

“Every five years, I celebrate the achievements with the automotive community through a commemorative vehicle,” said Steve Saleen, CEO, Saleen Automotive. “This year I am delighted to release three variations of our SA-30 model that will capture the essence of Saleen style and performance that will truly place elegance and power in the hands of the very few.”

A total of thirty Saleen SA-30 vehicles will be produced with ten of each model; Saleen 620 Camaro, 570 Challenger, and 302 Mustang. All Saleen SA-30 vehicles will share a Saleen Racing Heritage theme, despite the fact that each model is founded on a different platform.

The extremely limited production runs for each car are predicted to cause availability to end rapidly for these exclusive models. MSRP for the SA-30 model is set at $95,000 before options. Orders for this and other Saleen vehicles can be placed today at Saleen dealers nationwide, or by contacting Saleen directly for a personalized ordering process which concludes at the nearest Saleen Authorized Dealership.

For further information, please visit www.saleen.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

RF Micro Devices Inc. (RFMD) Receives Supplier of the Year Award from Huawei

Leading global high-performance radio frequency solutions provider RF Micro Devices announced it has received Huawei’s Supplier of the Year Award for 2013. Huawei is a world leader in providing information and communications technology (ICT) solutions. This marks the second time in three years that RFMD has received this prestigious “Golden Core Partner” award. Bob Bruggeworth, president and CEO of RFMD, accepted the award at a ceremony that took place on Nov. 21 at Huawei’s headquarters in Shenzhen, China.

A key component supplier to Huawei, RFMD supports the company on handsets/smartphones, supplying this leading handset maker with discrete antenna switches, antenna switch modules, power amplifiers, power management ICs and Wi-Fi low noise amplifiers. RFMD also provides Huawei with a variety of components for wireless infrastructure and point-to-point cellular backhaul.

An important strategic partner for Huawei, RFMD has provided the company with high-quality technology and new product development, field applications support, proactive local customer support and superb on-time delivery.

“This award is a testament to RFMD’s ability to deliver industry-leading technologies on time and in very high volumes, and we look forward to the continued expansion of our longstanding relationship,” said Xiong Lening, VP of the supply chain management department for Huawei.

For more information about RFMD, visit www.rfmd.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Progress in the Development of VistaGen’s (VSTA) AV-101 Prodrug Candidate for Treating Neuropathic Pain and Depression

With grant funding from the U.S. National Institutes of Health (NIH), biotechnology company VistaGen Therapeutics, Inc. has successfully completed Phase 1 development of AV-101, an orally available small molecule prodrug candidate. AV-101 is targeted at the multibillion-dollar neurological disease and disorder market, including depression and neuropathic pain, which is a serious and chronic condition that causes pain after an injury or disease of the peripheral or central nervous system. In support of the company’s nonclinical and Phase 1 clinical development of AV-101, the NIH awarded VistaGen more than $8.8 million in grant funding.

Also known as “L-4-chlorokynurenine” and “4-CI-KYN,” AV-101 is converted in the brain into 7-chlorokynurenic acid (7-CI-KYNA), an active metabolite and an agonist of the N-methyl-D-aspartate (NMDA) receptors. One of the most potent and selective blockers of the regulatory GlyB-site of the NMDA receptor, 7-CI-KYNA is a synthetic analog of kynurenic acid, which is a naturally occurring CNS regulatory compound.

AV-101 demonstrated very good levels of oral bioavailability in preclinical studies, as well as rapid and efficient transport across the blood-brain barrier and preferential conversion into 7-CI-KYNA at the site of seizures and potential neural damage in the brain and spinal cord.

VistaGen believes the safety studies completed in its AV-101 Phase 1 program may enable Phase 2 development of the drug for both neuropathic pain and depression. AV-101 has the potential to treat other neurological conditions, as well.

For more information, visit www.vistagen.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Galena Biopharma, Inc. (GALE) Receives Bullish Review at Seeking Alpha

Galena Biopharma has been highlighted in a Seeking Alpha article for its performance in developing breakthrough oncology treatments for various forms of cancer.

Contributing writer Kingmaker discusses the company’s Folate Binding Protein (FBP) and financial position, as well as provides a technical chart, before concluding that, “Galena Biopharma appears to be one company that deserves at least a small allocation of capital. By building a diversified portfolio of breakthrough treatments and products, corporate management appears to be serious about building a global biotechnology company that can grow significantly during the years to come.”

To read the article in its entirety visit http://seekingalpha.com/article/1857581

Galena is currently conducting a phase 1 FBP trial to prevent endometrial and ovarian cancer recurrences in patients who have already undergone therapy and are disease-free. So far, the company has determined optimal dose and found FBP’s toxicity to be minimal in addition to favorable follow-up.

“Investors should also note the results from the company’s 6-month follow-up. The vaccine group only demonstrated 2 recurrences, a total percentage of 13.3 percent. That compares extremely favorable to the number of recurrences (4) in the control group, which was a 25 percent rate,” writes Kingmaker.

For the third quarter of 2013, Galena reported an improvement of approximately $56.8 million in cash, cash equivalents and short-term investments, as compared to previous quarters. The article recaps the company’s financial performance and notes upcoming potential.

“As investors soak in the promising early results from the FBP Phase 1 trial, they should also be aware that Galena continues to push forward with NeuVax (used in the treatment of breast cancer). The company expects to complete the NeuVax Phase 3 enrollment early next year. Galena also expects to announce interim results based upon 70 events by the summer of 2014 at the very latest. If positive, these interim results will likely send the shares to new 52-week highs. In fact, biotech companies typically see significant share price runs over the course of a Phase 3 trial, up until the results are announced. If investors have a reason to believe the results will be positive, Galena could end up being the biotech stock of 2014,” writes Kingmaker.

For more information, visit www.galenabiopharma.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

MELA Sciences, Inc. (MELA) Video Chart for Friday, November 22, 2013

MELA has made a double bottom pattern with support at 65 cents. The last time the chart bounced off these levels, the move was 60 percent to a high of $1.04, putting it on watch for continued upward pressure again off the base.

To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Thursday, November 21, 2013

MagneGas Corp. (MNGA) Initial $276k Received for First Plasma Arc Flow Gasification Unit to Kazakhstan

MagneGas, the Tampa-based developer of a revolutionary liquid waste to hydrogen-based fuel known as MagneGas™ (very similar to HHO or Oxyhydrogen in post combustion), which is created using the company’s patented Plasma Arc Flow™ technology (using a ~10k°F plasma arc) that can turn almost any liquid waste into a clean, green fuel that is ideal for a wide range of uses, reported reception today of the initial $276k payment ($223k remaining) from Kazakhstani customer, Astana TechCom, Inc., which has purchased a custom-built mobile Plasma Arc Flow gasification system.

The MagneGas fuel is a marvel of metal cutting prowess, it cuts cleaner than acetylene and emits oxygen when burned as a byproduct, making it ideal for metal work being done in tight fits, such as inside the hull of a ship. MNGA has a solid track record rolling out custom builds of their MagneGas recyclers and the units provide an exceptionally cost effective way to do on-site liquid waste conversion, functioning in both a complete gasification mode (best for oily or hazardous wastes) that is fuel production focused and in a sterilization mode, allowing for high-cap agricultural waste, sewage, and sludge processing. Both modes produce MagneGas, as well as easily handled carbon precipitates that are being developed for use in the manufacturing of electrodes, but in the sterilization mode the recycler produces a completely sterilized and liquid which is retained within the sealed environment of the unit. MagneGas is essentially interchangeable with natural gas and thus provides certain obvious logistical advantages to customers from an implementation standpoint as well.

Astana TechCom, located in the capital of Kazakhstan, will trial the small (custom-built for demoing) mobile gasification system before targeted energy, medical facility and university interests, who are natural primary first consumers of the technology. This deal provides MNGA with a highly localized marketing tool administrated by a well-connected Kazakhstani company and represents a major step into Central Asian markets for this transformative technology, a technology which is destined to make a significant impact sector-wide across the industrial gas, as well as liquid waste treatment markets. On-site sterilization and fuel production for cooking, heating and even co-combustion with fossil fuels makes MagneGas an extremely attractive option for the region as a whole, especially considering the relative remoteness of certain operations or lack of underlying nearby infrastructure.

Astana TechCom Director and University Scientist, Dr. Ascar Aringazin, hailed the custom mobile Plasma Arc Flow gasification platform as an exceptional way to help proliferate the technology to a larger market throughout Central Asia and projected mounting regional distribution as an inevitable result of showcasing the tech in this area. Dr. Aringazin emphasized the strong economic, as well as diplomatic ties between the U.S. and Kazakhstan that stretch back to 1991, obviously proud of Kazakhstan being the leaping off point for the technology to broader Central Asian markets and obviously quite keen as well to fully seize/maintain a leadership role in MagneGas system distribution.

CEO of MNGA, Ermanno Santilli, touted the small footprint of the custom unit and the synergies presented by not having to transport liquid wastes around due to custom unit’s mobility. Santilli explained that this mobile design is the perfect way for Astana TechCom to demo the unit to customers and distributors, who will be able to get a first-hand look, personally verifying the liquid sterilization/gasification capabilities of this readily scalable technology. The sale of this one unit will rapidly accelerate market penetration in this underserved region and Santilli was particularly eager to get a look at and share test results from Kazakhstan’s energy and medical industries.

The versatility of the MagneGas fuel, the fact that the technology can be up-scaled on a site by site basis to meet the exact needs of the client and the benefits of not having to deal with costly, as well as problematic transportation of liquid wastes, all contribute to MagneGas having a bright future in Central Asia. Final payment and delivery of the company’s first unit into this huge market is anticipated for early next year (February) and the Astana TechCom acquisition really should be a signal to investors about how robust MNGA’s systems have truly become since the company’s inception back in 2007.

To get a closer look head over to the MagneGas Corporation website at www.MagneGas.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Jameson Stanford Resources Corp. (JMSN) Strategically Focused on Utah’s Rich Mineral Deposits

Jameson Stanford Resources is the owner and operator of three mines in Utah, the nation’s fourth-largest mineral producing state. Jameson’s project portfolio is comprised of the Star Mountain Mining District, Beaver County, Utah; the Spor Mountain Mining District, Juab County, Utah; and the Ogden Bay area, Weber County, Utah.

The company in 2012 acquired Bolcan Mining Corp., which was formed to develop certain mining projects and claims located in the Star Mining District, a project covering nearly 5,000 acres and suggested total inferred reserves of more than 100 million metric tons of copper ore, as well as reserves of silver, gold, PGM and other base metals. By acquiring Bolcan as a wholly owned subsidiary, Jameson received certain lode mining claims and mineral leases for Star Mountain and immediately began work on site. Jameson is now working with the first deliveries of copper and has already established customers awaiting ore production.

Jameson’s Spor Mountain project in western Utah consists of nine lode mining claims and three metalliferous mineral lease sections. The district is home to the world’s largest economic deposits of beryllium, and in the past has produced uranium. Jameson’s planned project activities at Spor Mountain during 2013 are limited to exploration, though with favorable economic factors, the company anticipates startup of production/mining operations in 2014.

Ogden Bay Minerals is a developing mineral excavation project on federal protected wetlands, canals and river systems running through 25 square miles of land comprising the North Delta. This project contains large deposits of alluvial mineral deposits that are created and replenished from 125 miles of river flow from the nearby Wasatch Mountain Range. Jameson believes that gold, silver, silica and other commercial metals and minerals can be efficiently extracted from this area by gravity separation methods.

For more information, visit www.jamesonstanford.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Commtouch® (CTCH) Announces Changes to its Executive Team

Leading provider of Internet security technology and cloud-based services Commtouch® announced a few changes made within its senior management team in order to support its ongoing transformation strategy from a technology service provider to a complete cloud-based Security-as-a-Service provider. These appointments will strengthen the executive teams focus on the company’s long-term growth strategy, while continuing to ensure operational excellence.

Effective immediately, Shlomi Yanai has been recruited to the role of president where he will focus on Commtouch’s strategic growth initiatives, transitioning the position of chief executive officer to Lior Samuelson, who currently sits as Chairman of the Board of Commtouch. He is set to keep continued focus on the company’s operational excellence. Samuelson, who has a long-standing relationship with Commtouch, holds an extensive career that includes serving as chairman, CEO and board member of a number of companies in technology, telecom, financial services and management consulting.

“These management changes strengthen Commtouch’s ability to evaluate and capitalize on emerging business opportunities more quickly,” stated Lior Samuelson, CEO and Chairman of the Board. “The Board of Directors is very pleased that Shlomi accepted this position.”

“These new roles for Lior and me allow us to continue the strong partnership we have built over the past few years. I am more confident in the strength of the organization to take advantage of the most critical opportunities to build long-term sustainable growth,” commented Shlomi Yanai.

Shlomi Yanai will retain his seat on the Commtouch Board of Directors.

To learn more, please visit www.commtouch.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

The Rapid Growth and Diversification of Chanticleer Holdings, Inc. (HOTR)

The restaurant business is notoriously fickle. For every super success story there are probably a thousand failures. New concept restaurants, fast food, and casual dining establishments seldom succeed. The proven way to profitability is to partner with an established brand then leverage the concept and business model. Growth and diversification then determine success.

With experienced and savvy management, this is exactly how Chanticleer Holdings is growing so rapidly. The company is expanding one of the most successful and recognized US restaurant brands in multiple international markets. Chanticleer currently owns and operates in whole or part seven Hooters restaurants in its exclusive international franchise territories of South Africa, Hungary, and parts of Brazil. The company also has joint ventured with the current Hooters franchisee in Australia, and, with a group private equity investors, acquired Hooters of America (HOA), a privately held company. Today, HOA is an operator and the franchisor of over 412 Hooters® restaurants in 28 countries.

Chanticleer’s aggressive growth strategy doesn’t stop there. In September the company announced that they had completed the 100% acquisition of American Roadside Burgers, a five store hamburger chain operating in North Carolina. Chanticleer plans to continue expansion of the American Roadside chain as opportunities occur and this acquisition brings a wholly owned brand under Chanticleer and potentially adds future revenue and profits.

This has been a very busy month for Chanticleer. The company finalized the acquisition and took operating control of the already profitable Hooters in Nottingham, England. Also, Chanticleer just entered into a Subscription Agreement for a controlling interest in the Just Fresh restaurant chain. Just Fresh currently operates five restaurants in North Carolina area that offer fresh-squeezed juices, gourmet coffee, fresh-baked goods and premium-quality, made-to-order sandwiches, salads, and soups. Chanticleer plans to expand the brand as opportunities arise.

With their rapid growth and diversification, Chanticleer Holdings is obviously focused on the path to a super success story.

For more information, visit www.chanticleerholdings.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Methes Energies, Inc. (MEIL) is “One to Watch”

Methes Energies, Inc. uses its own proprietary technology to produce high-quality biodiesel processors and systems to capitalize on the growing demand for renewable energy, surging energy prices, and the value of biodiesel as a practical and realistic long-term replacement for conventional diesel fuel. The Company’s processors are flexible and can use a variety of virgin vegetable oils, used vegetable oil and rendered animal fat feedstock, allowing operators to take advantage of feedstock buying opportunities. Methes Energies also markets and sells high-quality biodiesel fuel produced at its 1.3 MGY (5 MLY) showcase production facility in Mississauga, Ontario, and at it’s recently commissioned 13 MGY (50 MLY) facility in Sombra, Ontario, to customers in the U.S. and Canada.

Methes Energies’ broad range of expertise and solutions include all aspects of the engineering, manufacturing, production, logistic, marketing and distribution processes. Among other services, the company leverages its cutting-edge biodiesel processors, pre-treatment systems, and other solutions to address real and specific biodiesel production challenges for large and small-scale biodiesel producers and entrepreneurs seeking to produce their own fuel.

In 2007 the company introduced the Denami 600, the industry’s first compact, full automated continuous flow biodiesel processor designed to run on a wide variety of feed stocks. This reliable, cost-effective and superior method of producing top-grade biodiesel exceeds current ASTM standards.

The company also sells feedstock to its network of biodiesel producers, selling their biodiesel production and providing clients with proprietary software to operate and control their processors. Methes Energies remotely monitors the quality and characteristics of its clients’ production, upgrades and repairs their processors as necessary, and advises clients on adjusting their processes to use varying feedstock to improve the quality of their biodiesel.

As a competitive and highly respected revenue-generating player in the North American biodiesel sector, Methes Energies is fast building a network of biodiesel operators and facilities to capitalize on buying power and economies of scale. The North American demand for biodiesel is sizeable and the company is well positioned for global expansion throughout Europe, South America, Africa and Asia.

Key Investment Highlights

• Provides Best-in-Class Biodiesel Solutions to Renewable Energy Market
• Developer of Revolutionary, Superior Biodiesel Processors
• Capitalizing on Booming North American Biodiesel Market
• Positioned for Global Expansion to Meet Rising Demand

For more information, visit www.methes.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Wednesday, November 20, 2013

Calpian, Inc. (CLPI) Operations Backed by Highly Qualified, Experienced Management Team

Company chairman and CEO Harold Montgomery has been in the payment processing business since 1987. Before leading the formation of Calpian, he was the CEO of A.R.T. Holdings, Inc. (dba Calpian from 2002 to 2009), a company that underwrote and acquired hundreds of merchant portfolios totaling approximately 35,000 merchants. His 23 years of payments industry experience includes work in the payments business including in the ISO, merchant payment processing and mobile payments vertical markets and in sourcing capital. He’s a widely known industry authority, a speaker at regional and national trade shows and writes a regular monthly column for Transaction World Magazine.

Craig Jessen is the president of Calpian, contributing his payment processing experience that started in 1991. He was the President of A.R.T. Holdings where he was responsible for the sourcing, underwriting, negotiation and funding of these acquisitions. Jessen has 23 years of experience in the payments industry, including experience with the ISO space, merchant payment processing, sales training, and business development and sourcing capital.

Calpian CFO David Pilotte has a broad-base of experience across many industries, and brings to Calpian more than 22 years of experience leading middle-market public companies including roles as CFO, COO, corporate controller, treasurer and independent advisor. During that time he has led 10 M&A transactions totaling $1.2 billion in value, raised and managed more than $550 million in financing and led public companies ranging from startups to those with over $700 million in revenues.

Laird Cagan is a director for Calpian and is managing director and co-founder of Cagan McAfee Capital Partners, LLC (“CMCP”), a private investment firm and merchant bank he founded in 1990. Since 2000, CMCP has founded and/or funded and taken public, 10 companies in a variety of industries including energy, alternate energy, healthcare and information technologies. CMCP portfolio companies have raised over $600 million.

Shashank Joshi is the managing director of Calpian’s Money-on-Mobile and has more than 18 years of professional experience in the areas of IT and ITES, outsourcing, transition and management consulting. He has been a pioneer in the successful execution of merchant cash advance and merchant processing businesses through the offshore route. Joshi has cross-border global experience of more than six years in “simplifying payments.”

For more information, visit www.calpian.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

TigerLogic Corp. (TIGR) Updates Social Engagement Platform

Today, TigerLogic announced that it has made a significant update to its social, fan engagement, and visualization platform in the form of Postano 2.0. The new SaaS platform will give marketers the never-before-had access to fan activity across major social networks. They can now easily curate and publish the best of this content into social hubs, event displays, in-store displays, command centers, and broadcast it through mobile apps.


”Curating fan content is a compelling way to increase loyalty and activate fan behavior. Postano’s new platform provides our clients with the tools necessary to see, and publish, the best social content to stimulate earned media and drive revenue. Our recently announced financing coupled with the launch of Postano 2.0 creates a unique and compelling enterprise approach to the social mobile marketplace,” said Tom O’Keefe, TigerLogic’s SVP-Social and Mobile.

These days, marketing is all about engaging with fans. And now, more than ever, the ability for people to instantly share posts, images and video increases a marketing team’s opportunities to interact with users.

Social and digital managers, CMOs, event producers, and heads of retail at all levels want to leverage the latest in fan-based, image-centric web publishing and display technology. Brands already love Postano for its power to immediately source content from major social networks and its ability to aggregate and curate content for truly engaging fan experiences. Now, they’ll have even more to love with new updates to Postano 2.0, including:

• -One single, comprehensive dashboard
• Fast moderation workflow for efficient social curation
• First native mobile moderation apps for the iPhone and Android phones
• Complete customizable HTML5 for content on any size screen

“Postano 2.0 was redesigned from the ground up as a SaaS platform with scale and performance as critical components,” said TigerLogic’s Justin Garrity, SVP of Product and Marketing for Postano. “Postano 2.0 has been designed to quickly surface that content and facilitate monitoring and curation from any location 24/7. The redesigned Postano 2.0 web app with split view moderation and the new native iPhone and Android apps set a new standard for social monitoring and curation platforms.”

To learn more about postano, please visit www.postano.com

For more information, visit www.calpian.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Tuesday, November 19, 2013

MamaMancini’s Holdings, Inc. (MMMB) Demonstrates Strength and Strategy in Growth Initiatives, Financial Results

MamaMancini’s manufactures and markets specialty pre-prepared frozen and refrigerated “all natural” food products. The company on its website also provides consumers with food-related blogs, unique recipes, and video cooking instructions.

As an emerging company, MamaMancini’s offers a small assortment of Italian food products in gourmet catalogs as well as on approximately 19,500 shelves in supermarkets and club stores across the nation. This compares to inventory stocked on approximately 12,000 shelves a year ago.

Through successful efforts to expand its distribution channel, MamaMancini has established distribution partnerships with major retailers such as Costco, Publix, Shop Rite, Price Chopper, Redners, Pathmark, A&P, Waldbaums, Food Emporium, Whole Foods, Shaw’s Supermarkets, Kings, Key Foods, Giant Eagle, Stop-n-Shop, Giant Stores, Food Town, Kroger, Winn Dixie, Market Basket, Albertsons, Shoppers, Wal-Mart, Marsh’s Supermarkets, Bashas, Bi-Lo, Central Markets, Weis Markets, Ingles, and The Fresh Market.

These strong distribution channels have driven third-quarter triple-digit revenue growth and add weight to the company’s guidance for continued increases throughout the fourth quarter of 2013.

Third-quarter revenues increased 124 percent to $2.17 million compared to revenues of $0.97 million reported in the third quarter of 2012, reflecting an increase in the number of locations that carry the company’s products.

SG&A for the quarter was $1.1 million compared to $712,000 as the company ramped up its advertising and marketing to create brand awareness. Looking ahead, MamaMancini plans to launch radio, social media and other marketing campaigns, and as a result of ongoing and future efforts expects fourth-quarter revenue to grow between 133-158 percent to between $2.8 million and $3.1 million.

For more information, visit www.mamamancinis.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Galena Biopharma, Inc. (GALE) Anticipates Continued Growth on Strong Clinical Pipeline, Abstral Performance

Galena Biopharma is a developer of targeted oncology treatments designed to address major unmet medical needs to advance cancer care. As part of its overarching goals, Galena is seeking commercialization partners for its current clinical programs.

The company’s clinical development pipeline is headed by NeuVax™, which has been granted by the FDA a Special Protocol Assessment (SPA) for a phase 3 clinical trial testing the product’s efficacy to prevent breast cancer recurrence. NeuVax is currently undergoing this phase 3 testing in combination with Herceptin®; phase 2 for breast cancer; and phase 1 for prostate cancer.

Galena is also developing Folate Binding Protein-E39 (FBP), a targeted vaccine aimed at preventing the recurrence of ovarian, endometrial and breast cancers. FBP is in phase 1 studies for this indication.

The company in October officially launched Abstral®, its sublingual (under the tongue) rapid-acting formulation of fentanyl for the management of breakthrough cancer pain in patients who are tolerant to background opioid pain-relief therapy.

When the company earlier this month reported third-quarter revenues of $1.2 million, the results reflected significant contribution of Abstral sales ahead of the product’s official launch and promotional efforts slated for the fourth quarter.

Abstral has achieved considerable success as the leading rapid acting fentanyl product in Europe, where it achieved full-year sales of $54 million by ProStrakan/Kyowa Hakko Kirin in 2012. By the second half of 2012, the average volume market share of Abstral in the major European markets reached 29%. Abstral is marketed in Canada by Paladin Labs, and has been filed for regulatory approval in Japan by Kyowa Hakko Kirin Co Ltd.

The U.S. market for rapid acting fentanyl products is also growing, and in 2012 reached $400 million. Based on this trend and the company’s initial commercial success with Abstral, Galena said it expects to see continued growth in the fourth quarter of 2013 and fiscal 2014.

For more information, visit www.galenabiopharma.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

New Contract, Further Extension of Existing Contracts for Command Security Corp. (MOC)

Command Security, a provider of uniformed security officers, aviation security services, and support security services to entities throughout the United States, announced it has been awarded a five-year follow-on contract to provide security services in the Eastern U.S. for a major transportation company. Command Security simultaneously announced an additional extension – through Feb. 28, 2014 – of existing Eastern and Western region security service contracts with this same major transportation company.

The five-year follow-on contract will cover a geographic area extending from Maine to Virginia and into western Pennsylvania. The contract will go into effect upon completion of final negotiations, which are anticipated to be completed before the Feb. 28 contract extension expires. No award decision has yet been made regarding the Western region.

As announced previously by the company, contracts with one security services customer – representing 24 percent of Command Security’s total revenues – were originally scheduled to expire on May 31, 2013, but the contracts have been extended twice since that time – first through Aug. 31 and then through Nov. 30. As also previously disclosed, this same customer initiated – and invited Command Security to participate in – a competitive bidding process for the continued performance of these and other services in the Eastern and Western regions of the U.S.

“We are very pleased to receive this follow-on contract award for the Eastern region as well as the contract extensions in both regions through February,” said Command Security CEO Craig Coy. “This affirms the hard work, commitment and professionalism of the Command Security Team. And it further demonstrates our unique ability to satisfy national customers by securing their assets across broad geographic footprints while simultaneously maintaining the flexibility to quickly respond to the diversity of their needs at the local level.”

For more information, visit www.commandsecurity.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Monday, November 18, 2013

Methes Energies International Ltd. (MEIL) Record Biodiesel Shipments, Poised To Expand Production Capacity, Solid Turnkey Processor Business

Methes Energies is responsible for a series of biodeisel production facilities in Canada (roughly 16.9M gallons/year total capacity), as well as manufacturing and marketing top-of-the-line, continuous flow, fully-automated turnkey biodiesel processing units and multi‐stage filtration/absorption cold soak systems to prevent biodiesel crystallization. They even handle the proprietary control software for their processors which enables the company to do remote quality oversight of clientele production.

The company’s Denami line of biodiesel processors, available in their big daddy 3000 model (700 gallons/hour continuous flow) and smaller 600 model (158 GPH) formats, are extremely compact and well designed. These all stainless steel units have a built-in methanol recovery system and come rigged with a complete touchscreen-based PLC (programmable logic controller) systems architecture. The company doesn’t just help clients ensure their production is top-notch though, they handle hardware repairs and upgrades, as well as advising clients on how to best tune their overall throughput, with learned guidance on things like the best ways/types of feedstock variation for creating an optimum final product. Their turnkey Denami processors come with a full lifetime warranty and the company does on-site personnel training for the units as well as client feedstock evaluation/validation, making these systems a sure fire way for biodiesel producers to easily stay competitive as the industry continues growing. The company provides a whole range of services for new and existing clients as well, ranging from consultation, through sales and on into troubleshooting or more nuanced aspects of a client’s production objectives (off-spec biodiesel production and the like).

The company’s own facilities in Ontario, a 1.3 MGY showcase/R&D facility in Mississauga and their much larger 13 MGY plant in Sombra, are run via wholly-owned subsidiary, Methes Energies Canada Inc. This approximately 14.3 MGY production footprint has recently been accelerated towards capacity with the closing of a $1.5M working capital facility (reported Aug 16), allowing for the ready uptake of additional feedstock and round-the-clock operation of the primary Denami 3000 processors at the facility. The company has done a full review of their Sombra expansion plans and found that current hardware, once retrofitted to flow at double capacity, will be able to meet the 26 MGY production target; a huge efficiency savings over putting in more production units. MEIL also plans to install a distillation column at Sombra to further improve processing quality of the biodiesel, taking full advantage of their working capital facility to refine revenue generation metrics.

Ever since the Canadian government implemented a 2% national biodiesel mandate back in early 2011 there has been steadily increasing demand throughout target markets in North America and the company has just recently managed to ship out a new record from their Sombra plant, as 18 rail cars loaded with biodiesel left the facility in October (over 485k gallons), shattering their previous monthly record of 8 cars back in April of this year. This huge jump in sales and production was directly attributable to strong demand fundamentals and securing of the working capital facility. Success which has led management to initiate further discussions with their current Toronto-based lender about further expansion of the facility to accommodate even more production.

MEIL is on track for similarly robust production numbers in Q4 and stands to make as much product in the last quarter of this year as in the whole of fiscal 2012, an astounding growth story. The company is intent on fully leveraging their momentum and has made significant progress in becoming an accredited BQ-9000® Producer with the U.S. National Biodiesel Accreditation Program too, a program which combines ASTM standard (one of the biggest voluntary standards developing organizations on earth and the leading authority) for biodiesel, ASTM D6751, and a quality systems program that covers the gamut of usage logistics from testing, to shipping and storage. This key accreditation signifies passage of a rigorous inspection and review process by an independent auditor, ensuring that quality control over production is fully implemented and that fuel produced is almost never inadequate; a further, highly visible sign to markets in the U.S. and Canada that they are getting premium biodiesel when they shop with MEIL.

Ethanol producers across North America are really taking notice of the Denami line in recent months and the 600/3000 units are seeing considerable traction as a modular solution for Ethanol plants, with 2013 marking a major increase in sales as producers realize the benefits of extracting the corn oil from their corn before processing it into Ethanol. In fact, the appeal is strong enough that some producers are even going whole-hog, converting the corn oil to biodiesel in order to grab that extra revenue, something which is making the company’s biodiesel processing hardware more and more attractive, not just in North America, but on the global stage as well. The company is well positioned to become a global supplier of turnkey production hardware and has a solid revenue stream of their own via their biodiesel production footprint to back up this play. Moreover, the easy expansion potential of the production footprint means the company can ramp up fuel sales to support their growing equipment business in concert with demand.

Markets should hear anytime now from MEIL regarding their review of proposals from two different, independent third-party EPA Quality Assurance Plan (QAP) providers, as to which they have selected for navigating the Renewable Identification Number QAP scheme, designed by EPA to speed up imports and enable smaller producers to do business more readily. This move by the company will pave the way for a larger export market to the U.S. and investors should keep an eye out for this announcement, as well as news about the retrofitting at Sombra.

More about Methes Energies International Ltd. is available online at www.Methes.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html



Boston Therapeutics, Inc. (BTHE) Presenting at Elsevier Therapeutic Area Partnerships 2013 Conference

Boston Therapeutics, a company focusing on the development of diabetes treatments using complex carbohydrate chemistry, continues to make progress in raising public awareness of its diabetes drug’s potential. The company announced in a news release today it will be presenting at the Elsevier Therapeutic Area Partnerships 2013 Conference, where it was selected as one of 10 “Top Projects to Watch” within the category of cardiovascular/metabolic diseases. Mr. Kenneth A. Tassey, Jr., President of Boston Therapeutics, will be presenting information about the diabetes drug PAZ320 at the conference.

From 2:15 to 3:05 PM on Tuesday, November 19, 2013, at the Hyatt Regency in Boston, Mr. Tassey will discuss how PAZ320 was recently found to exhibit Type 2 diabetes management efficacy in 45% of patients in an FDA Phase 2a clinical trial. PAZ320 is a non-systemic chewable tablet that lets patients manage their post-meal blood sugar levels, by targeting enzymes that digest sugar during digestion.

Mr. Tassey said, “TAP 2013 promises to be one of the key meetings of the year within the cardiovascular/metabolic disease area. We are pleased with this opportunity to educate attendees about the potential benefits of PAZ320, and are honored to be named a ‘Top Project to Watch’ by the independent panel.”

Since it was first started almost a decade ago, the conference has come to be one of the premier events in biopharmaceutical partnering. The event gathers the leading industry entrepreneurs and thought leaders to hear of the latest developments in biopharmaceuticals as well as provide quality networking opportunities. The “Top Projects to Watch” picks are determined by a panel of independent experts who screen hundreds of compounds and select the ones with the most potential as future products. Their criteria include: large market, large unmet need, with increasing opportunity; history of the molecule and drug; strong science; strong company; diversity of indications; potential for new opportunities beyond the initial indications; and multilevel partnering opportunities.

For more information, visit: www.bostonti.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Friday, November 15, 2013

Prosensa Holding N.V. (RNA) Awarded Best Biotech Pipeline 2013 in Inaugural ROAR Awards

Dutch biopharmaceutical company Prosensa Holding N.V. announced it has been awarded “Best Biotech Pipeline 2013” in the Rare & Orphan Advocacy and Research (ROAR) Awards, which were given for the first time this year.

The inaugural ROAR Awards were announced during the fourth annual World Orphan Drug Congress Europe, which took place Nov. 14-15 in Geneva, Switzerland. The awards have been instituted to recognize and honor the achievements of organizations and individuals from industry, patient and rare disease advocacy communities.

Prosensa’s focus is on rare diseases with high unmet medical need, developing treatments for patients who presently have very limited options. The “Best Biotech Pipeline” award was given in recognition of the broad scope of the company’s orphan drug pipeline, particularly its groundbreaking work in Duchenne muscular dystrophy (DMD), myotonic dystrophy, and Huntington’s disease.

With its primary focus on rare neuromuscular and neurodegenerative disorders with large unmet medical need, Prosensa is engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. The company’s portfolio currently includes six compounds for treating DMD, all of which have been granted orphan drug status in the U.S. and the European Union. Through an innovative technique called exon-skipping, these compounds provide a personalized medicine approach for treating different populations of DMD patients.

For more information, visit www.prosensa.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html